SANTA
CLARA, Calif., April 28,
2023 /PRNewswire/ -- The board of directors of Semler
Scientific, Inc. (Nasdaq: SMLR), is pleased to announce that it has
appointed Doug Murphy-Chutorian,
M.D., former CEO and a current member of the board of directors as
chief executive officer (CEO) on an interim basis with immediate
effect. The board intends to conduct a global search for a
permanent CEO.
"We are delighted that Doug has changed his near-term plans in
order to return as interim CEO," said Eric
Semler, the chairman of the board. "We greatly value Doug's
long history with the company as both its CEO and one of its
largest stockholders."
About Semler Scientific, Inc.:
Semler Scientific, Inc. is a company that provides
technology solutions to improve the clinical effectiveness and
efficiency of healthcare providers. Semler Scientific's mission is
to develop, manufacture and market innovative products and services
that assist its customers in evaluating and treating chronic
diseases. Semler Scientific's patented and U.S. Food and Drug
Administration (FDA), cleared product, QuantaFlo®, is a rapid
point-of-care test that measures arterial blood flow in the
extremities to aid in the diagnosis of cardiovascular diseases,
such as peripheral arterial disease (PAD) and heart dysfunction
(HD). QuantaFlo® is used by Semler Scientific's customers to more
comprehensively evaluate their patients for risk of mortality and
major adverse cardiovascular events (MACE), which are associated
with a positive QuantaFlo® test. Semler Scientific has an agreement
with Mellitus Health, Inc. (Mellitus) to exclusively market and
distribute Insulin Insights™, an FDA-cleared software
product that recommends optimal insulin dosing for diabetic
patients in the United States,
including Puerto Rico, except for
selected accounts. Semler Scientific has made investments in
Mellitus, in NeuroDiagnostics Inc., a privately held company doing
business as SYNAPS Dx, whose product, Discern™, is a test
for early Alzheimer's disease, as well as Monarch Medical
Technologies LLC, a privately held company whose product EndoTool™
offers a technology-enabled approach to inpatient glycemic
management. Semler Scientific continues to develop additional
complementary innovative products in-house, and seeks out other
arrangements for additional products and services that it believes
will bring value to its customers and to the company. Semler
Scientific believes its current products and services, and any
future products or services that it may offer, positions it to
provide valuable information to its customer base, which in turn
permits them to better guide patient care. Additional information
about Semler Scientific can be found at
www.semlerscientific.com.
INVESTOR CONTACT:
Susan
A. Noonan
S.A. Noonan Communications
susan@sanoonan.com
917 513 5303
View original content to download
multimedia:https://www.prnewswire.com/news-releases/semler-scientific-names-doug-murphy-chutorian-md-as-interim-ceo-301811215.html
SOURCE Semler Scientific, Inc.